昊海生物科技(06826.HK)斥1.35亿人币购医学美容业务逾38%持股
昊海生物科技(06826.HK)公布,与Welly Bloom Limited及Refined Beauty Limited订立购股协议,公司将收购欧华美科(天津)医学科技合共约38.23%股权,代价为1.35亿元人民币(下同)。欧华美科(天津)医学科技拥有射频美肤设备、玻尿酸及几丁糖生物材料,及激光美肤设备等三大产品线。
公司并订立增资协议,向欧华美科(天津)医学科技出资7,000万元,公司於收购及增资後将持有其股权总额63.64%。根据增资协议,如欧华美科(天津)医学科技的2021年、2022年及2023年净利润分别不少於600万元、1,800万元及3,000万元,创始股东有权自其2023年度审计报告出具日期起计三个月内,要求公司以现金或通过发行代价股份收购创始股东持有之欧华美科(天津)医学科技全部股权。
另外,公司与创始股东将成立一家作为期权池的有限合夥企业,以向创始股东及欧华美科(天津)医学科技其他核心管理人员提供股权激励。创始股东与公司将按零代价或中国法律允许的最低价格,分别向期权池转让其所持有的欧华美科(天津)医学科技6.36%及3.64%的股权。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.